AXL

Across TCGA pan-cancer cohorts, AXL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AXL data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher AXL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AXL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where AXL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	II,III,IV	0.461	0.885	.006	32	view →
PDAC	DFS	Median	All	0.666	0.919	.001	25	view →
LUAD	DFS	Tertile	II,III,IV	0.183	0.653	.008	23	view →
HNSC	DFS	Median	All	0.685	0.882	.022	8	view →
UCEC	OS	Median	II,III,IV	1.000	0.609	.043	4	view →
CCRCC	OS	Quartile	III,IV	0.384	0.920	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AXL–LSCC (DFS)

Open the LSCC breakdown →